Editorial
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 16, 2018; 6(8): 161-166
Published online Aug 16, 2018. doi: 10.12998/wjcc.v6.i8.161
Biosimilars: Review of current applications, obstacles, and their future in medicine
Flyn Kaida-Yip, Kaivalya Deshpande, Trishla Saran, Dinesh Vyas
Flyn Kaida-Yip, College of Medicine, California Northstate University, Elk Grove, CA 95758, United States
Kaivalya Deshpande, Department Of Surgery, Michigan State University, Lansing, MI 48912, United States
Trishla Saran, Department of Medicine, the University of Texas of the Permian Basin, Odessa, TX 79762, United States
Dinesh Vyas, Department of Surgery, Texas Tech University, Odessa, TX 79763, United States
Author contributions: Vyas D contributed with concept design; Kaida-Yip F contributed with research, write-up, editing; Vyas D, Saran T, Deshpande K and Kaida-Yip F contributed with the final approval.
Conflict-of-interest statement: All authors have no stated conflicts of interest related to this publication.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dinesh Vyas, MD, Associate Professor, Department of Surgery, Texas Tech University, 701 West 5th Street, Suite 2263, Odessa, TX 79763, United States. dvyas@sjgh.org
Telephone: +1-314-680134 Fax: +1-314-2607609
Received: March 27, 2018
Peer-review started: March 27, 2018
First decision: April 10, 2018
Revised: May 17, 2018
Accepted: June 26, 2018
Article in press: June 27, 2018
Published online: August 16, 2018
Processing time: 142 Days and 11.3 Hours
Core Tip

Core tip: This study elucidates the unique properties of biosimilars as a drug class and their effectiveness for inflammatory bowel conditions in lieu of first line biologics.